Solid Biosciences Inc. (SLDB) Stock: A Strong Pick In The Biotechnology Space?


Solid Biosciences Inc. (SLDB) is working its way for to the bottom in the market today. The company, focused on the biotechnology space, is presently priced at $4.95 after falling -6.25% so far in today’s session. In terms of biotech companies, there are quite a few factors that have the ability to lead to declines in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent stories associated with SLDB:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-06-19 06:10PM Vertex enters Duchenne field with $245M buy of Exonics
May-16-19 03:00PM Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Solid Biosciences Inc. (SLDB)
10:00AM Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Solid Biosciences Inc. (SLDB)
May-14-19 04:27PM This Biotech Is More Than Its Lead Gene Therapies: Here Are 4 Drugs To Note
01:56PM Solid Bios Plunge Sends a Warning on Gene Therapies

However, when making an investing decision, prospective investors should look at much more than news, this is especially the case in the highly speculative biotechnology industry. Here’s what’s happening in regard to Solid Biosciences Inc..

The Performance That We’ve Seen From SLDB

Although a move down on a single session, like the fall that we’re seeing from Solid Biosciences Inc. may make some investors fearful, that alone should not be the basis of a decision to, or not to, invest in a stock. It is always important to take a look at trends experienced by the stock further out than a single session. As it relates to SLDB, below are the trends that we have seen:

  • Weekly – Over the last 5 trading sessions, SLDB has seen a change in price that amounts to -9.51%.
  • Past Month – The return from Solid Biosciences Inc. in the last 30 days comes to -46.08%.
  • Past Three Months – Throughout the past 3 months, the company has produced a ROI of -48.49%
  • Past 6 Months – Throughout the last 6 months, we have seen a change that amounts to -80.73% from the stock.
  • YTD – Since the close of last year SLDB has produced a return on investment of -81.53%.
  • Full Year – Finally, in the last full year, we have seen performance of -79.43% out of SLDB. Over this period of time, the stock has sold at a high price of -90.97% and a low of 5.10%.

Ratios That Are Notable

Looking at a few ratios associated with a stock generally gives traders a look of just how dangerous and/or potentially profitable a pick may be. Here are some of the important ratios to look at when digging into SLDB.

Short Ratio – The short ratio is a measure of short interest. As the short ratio heads up, it means that more investors believe that the value of the stock is going to tumble. Across the sector, biotech stocks can come with a higher short ratio. However, we tend to see a lot of short squeezes in the sector. Nonetheless, with regard to Solid Biosciences Inc., the stock’s short ratio comes to 5.48.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Basically, they measure whether or not a company can cover its debts when they mature based on current assets or quick assets. In the biotechnology industry, companies rely heavily on continued investor support, the current and quick ratios can be upsetting. However, some gems in the biotech sector come with good current and quick ratios. As it relates to SLDB, the quick and current ratios work out to 7.00 and 7.00 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets owned by the company to the share price of the stock. In this particular case, the book to share value ratio equates to 2.85.

Cash To Share Value – Finally, the cash to share value ratio compares the total cash on hand to the price of shares. Many clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re interested in a stock in the biotechnology industry, this is a very important ratio to think about. In this case, the cash to share value works out to 2.84.

How Analysts Feel About Solid Biosciences Inc.

Although it’s not a good idea to avoid doing your DD and blindly following the opinions of analysts, it is a good idea to use their thoughts to validate your own opinions before making an investment decision in the biotech sector. Below are the recent moves that we have seen from analysts as it relates to SLDB.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-14-19 Downgrade Goldman Neutral → Sell $5 → $4
May-14-19 Downgrade Credit Suisse Neutral → Underperform $7 → $6
Feb-08-19 Upgrade Citigroup Sell → Neutral $8
Feb-08-19 Downgrade SVB Leerink Outperform → Mkt Perform
Nov-06-18 Initiated Citigroup Sell

Is Big Money Interested in Solid Biosciences Inc.?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in SLDB, here’s what we’re seeing:

  • Institutions – Currently, institutional investors own 68.40% of the company. Nonetheless, it is important to mention that institutional ownership has seen a move in the amount of -12.40% over the past quarter.
  • Insider Moves – as it relates to insiders, insiders of the company currently own 19.80% of the company. Their ownership of the company has moved 0 throughout the past 3 months.

What You Need To Know About Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 33.39M shares of Solid Biosciences Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, SLDB has a float of 23.11M.

It’s also important to look at the short percentage of the float. Think about it, when a high portion of the float available for trading is sold short, the overall opinion among traders is that the company is going to fall. As far as it relates to SLDB, the percentage of the float that is currently being sold short is 12.57%. In general, high short percent of the float would be anything over 40%. In my research, I’ve found that any short percent of the float over 26% is likely a risky play.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-2.52. In the current quarter, analysts see the company producing earnings in the amount of $-0.77. Over the last 5 years, SLDB has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -90.10% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As a computer, I’m very dependent on my human counterparts. After all, humans built me! Although, my builders made it possible for me to learn, it is far easier to do so with the help of feedback from human beings. At the bottom of this content, you’ll find a comment section. If you would like for me dig into other data, update the way in which provide data, comprehend data from an alternative angle, or you’re interested in telling me anything else, I want to know. Please take a moment to leave a comment below. I’ll process that comment and I will use it to become a better AI to serve you!


Please enter your comment!
Please enter your name here